BCR Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A-549 human lung adenocarcinoma cells, engineered for targeted disruption of the BCR gene. BCR encodes a multifunctional protein that possesses GTPase-activating protein (GAP) activity toward the Rho family GTPases Rac1 and Cdc42, along with scaffold functions in signal transduction. This knockout model provides a powerful tool for loss-of-function studies, enabling investigation of BCR-dependent regulatory mechanisms in epithelial cancer cells without the confounding effects of residual protein expression.
The A-549 cell line was originally isolated from a 58-year-old Caucasian male with lung adenocarcinoma and serves as a widely accepted model of human alveolar basal epithelial cells. These cells are extensively employed in respiratory disease and oncology research, including studies of drug response, metastasis, and epithelial cell biology. The polyclonal knockout population retains the general characteristics of the parental line while lacking functional BCR protein, making it suitable for comparative phenotypic analyses.
BCR functions as a critical negative regulator of Rac1 and Cdc42 by accelerating GTP hydrolysis, thereby modulating actin cytoskeletal dynamics, cell migration, and proliferation. It acts downstream of cytokine receptors and Src family kinases, and upstream of effectors including PI3K, AKT, and the MAPK cascade. BCR directly interacts with ABL1, GRB2, SOS, and CRK, and participates in multiprotein complexes that integrate signals from cell surface receptors. In the BCR-ABL fusion characteristic of certain leukemias, constitutive kinase activity drives oncogenic signaling; however, wild-type BCR??s role in solid tumors remains less defined. Disruption of BCR in A-549 cells may perturb Rho GTPase cycling and downstream pathways such as PI3K/AKT/mTOR, offering a defined system to dissect its tumor-suppressive or oncogenic functions.
In A-549 lung adenocarcinoma cells, BCR knockout potentially alters cell adhesion, migration, and invasive capacity by relieving negative regulation of Rac1 and Cdc42. This model enables precise assessment of BCR??s contribution to epithelial cell morphology, cytoskeletal organization, and proliferative signaling. Additionally, it allows exploration of synthetic lethal interactions and drug sensitivity profiles in a lung cancer context, particularly with inhibitors targeting the PI3K/AKT/mTOR axis or Rho GTPase pathways. The polyclonal nature minimizes clonal artifacts while maintaining genetic perturbation.
Researchers can employ these cells in a variety of assays, including western blotting for BCR and downstream targets (e.g., phospho-AKT, phospho-ERK), Rho GTPase activation assays to quantify Rac1 and Cdc42 activity, and co-immunoprecipitation to map BCR interactomes with ABL1, GRB2, or STAT5. Functional studies such as proliferation, migration, and invasion assays provide insights into BCR??s role in lung cancer progression. The cells are also suitable for phospho-signaling analysis and CRISPR-based synthetic lethality screens. This knockout model supports drug response profiling and mechanistic investigations of Rho GTPase signaling in epithelial cancers. For additional information or custom inquiries, please contact Ascent Research.
